Schering-Plough offers medicines in the following
February 10 2016
Schering-Plough manufactured several pharmaceutical drugs,
the most well-known of which were the allergy drugs Claritin and Clarinex, an
anti-cholesterol drug Vytorin, and a brain tumor drug Temodar. These are now
available from Merck & Co.
Schering-Plough Corporation (Schering-Plough) is a global science-centered healthcare company. Schering-Plough discovers, develops and manufactures pharmaceuticals for prescription, animal health, and consumer markets. The Company operates in three segments: Prescription Pharmaceuticals, Animal Health and Consumer Health Care. The Prescription Pharmaceuticals segment discovers, develops, manufactures and markets human pharmaceutical products. The Animal Health segment discovers, develops, manufactures and markets animal health products. The Consumer Health Care segment develops, manufactures and markets over-the-counter, foot care and sun care products, primarily in the United States. The Prescription Pharmaceuticals segment offers human pharmaceutical products in six therapeutic areas, including cardiovascular, central nervous system, immunology and infectious disease, oncology, respiratory, and women’s health.
Allergy and Respiratory
Arthritis & Immunology
CAELYX (pegylated liposomal doxorubicin HCI) (Marketed internationally only)
INTRON A Injection (interferon alfa-2b recombinant)
Noxafil is manufactured by Schering Corporation, Kenilworth, NJ.
PDF INTRON A Prescribing Information (PDF 159K)
TEMODAR (temozolomide) Capsules
ETHYOL (amifostine) (Marketed internationally only)
Levitra medication for erectile dysfunction
Butenafine 1% cream (Lotrimin) for athlete's foot - Schering-Plough Health Care Products, Memphis TN.
Skin Disorders & Sun Care
Schering-Plough Corporation World Headquarters
2000 Galloping Hill Road
Kenilworth, N.J. 07033-0530
Telephone: (908) 298-4000
Schering-Plough Corp. Profit
October 2006 - Schering-Plough Corp. said its quarterly profit soared on increased sales of the cholesterol medicines it shares with Merck & Co. Inc. and strong demand for its other drugs, sending shares higher. Schering-Plough Corp., continuing to deliver on a turnaround promised by Chief Executive Fred Hassan, said third-quarter net profit rose to $287 million, or 19 cents per share, up from $43 million, or 3 cents per share, a year ago, which included a large charge. Global sales, which officially do not include cholesterol drugs Zetia and Vytorin that are co-marketed under a joint venture with Merck , rose 13 percent to $2.6 billion. Sales were bolstered by growing demand for arthritis drug Remicade, Nasonex allergy spray and brain cancer treatment Temodar.